CXL-1020, a nitroxyl (HNO) prodrug, enhances cardiac inotropy/lusitropy and Ca 2+ cycling in rats exhibiting abnormal relaxation, induces vasorelaxation, and augments cardiac function in canine models. It has been investigated for its potential in treating systolic and stable heart failure [1].

CXL-1020 (100 μg/kg/min; infusion for 30 min) ameliorates hemodynamics and cardiac function and enhances both diastolic and systolic performance in mice [1]. CXL-1020 (3 and 10 mg/kg/min; 4-hour intravenous infusion) improves left ventricular systolic and diastolic function in dogs with advanced heart failure [2]. Animal Model: Adult male Sprague-Dawley rats (250-350 g; induced cardiac dysfunction by isoproterenol) [1] Dosage: 100 μg/kg/min Administration: For 30 min Result: Improved hemodynamics and cardiac function in normal rats, and enhanced both diastolic and systolic performance in cardiac dysfunction mice. Animal Model: Dogs (coronary microembolization-induced heart failure) [2] 3 and 10 mg/kg/min Dosage: 3 and 10 mg/kg/min Administration: 4-hour intravenous infusion Result: Decreased systolic aortic pressure (AoP) modestly; significantly increased EF and deceleration time of early mitral inflow velocity (DT) and significantly lowered left ventricular (LV) end-systolic volume (ESV), LV end-diastolic pressure (EDP) and end-diastolic wall stress (EDWS) in a dose-dependent manner.